



Fig. S1. Imaging findings demonstrating the extent of the patient's metastatic disease. (a) Positron emission tomography-computed tomography (PET-CT) scan before initiation of BRAFi/MEKi targeted therapy showed widespread metastatic disease, whereas computed tomography (CT) scan performed 4 months after initiation of dabrafenib and trametinib showed significant regression of the number and size of metastatic lesions in (b) the spleen, (c) paravertebral muscles, and (c, d) abdominal wall muscles and subcutaneous tissue.